drugset / Trial / NCT04384991

HU007 Eye Drops in Patients With Dry Eye Syndrome

NCT04384991

Phase 3 Completed 216 enrolled Huons Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multicenter, randomized, double blind, Restasis-controlled non-inferiority, Phase III Study to evaluate the efficacy and safety of HU007 eye drops in patients With dry eye syndrome

Timeline

Start
2019-05-03
Primary completion
2019-12-05
Completion
2019-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.02 % Other
Subject Cyclosporine Peptide 0.05 % Other

Indications